Supplementary Material for: Percutaneous-Assisted versus Laparoscopic Hysterectomy: A Prospective Comparison

  • Emanuele Perrone (Creator)
  • Cristiano Rossitto (Creator)
  • Francesco Fanfani (Creator)
  • Stefano Cianci (Creator)
  • Anna Fagotti (Creator)
  • Stefano Uccella (Creator)
  • Giuseppe Vizzielli (Creator)
  • Carmine Vascone (Creator)
  • Stefano Restaino (Creator)
  • Camilla Fedele (Creator)
  • Farrah Layla Saleh (Creator)
  • Giovanni Scambia (Creator)

Dataset

Description

Objective: To evaluate the feasibility of percutaneous approach, we prospectively compared our experience in percutaneous-assisted hysterectomy (PSS-H) with that in a series of laparoscopic hysterectomies (LPS-Hs). Methods: In this multicentric cohort study, from May 2015 to October 2017, 160 patients affected by benign and malignant gynecological conditions were considered eligible for minimally invasive surgery (MIS): 80 patients received PSS-H and 80 LPS-H. In each group, 30 cases of low-/intermediate-risk endometrial cancer were enrolled. For both groups, we documented preoperative outcomes, postoperative pain, and cosmetic outcomes. Results: No statistically significant differences were noted in baseline characteristics or operative time. We observed significant differences in estimated blood loss: median of 50 cc (PSS-H) and 100 cc (LPS-H) (p = 0.0001). In LPS-H, we reported 4 (5.0%) intraoperative complications and 1 (1.3%) in PSS-H. Thirty-day complications were 4 (5%) in PSS-H and 11 (13.8%) in LPS-H (p = 0.058). No significative differences were found in visual analog scale score, despite a relevant disparity in cosmetic outcome (p = 0.0001). For oncological cases, the 2 techniques had comparable intra- and postoperative outcomes and oncological accuracy. Conclusions: In this study, we reported that PSS-H is comparable to LPS-H for intra- and perioperative outcomes and postoperative pain, while PSS-H seems to be superior in cosmetic outcomes and patient satisfaction. PSS-H may represent a valid alternative in ultra-MIS for benign gynecological conditions and low-/intermediate-risk endometrial cancer.
Dati resi disponibili2020
EditoreKarger Publishers

Cita questo